<DOC>
	<DOCNO>NCT00398398</DOCNO>
	<brief_summary>The combination capecitabine oxaliplatin 'backbone ' regimen , add new biologic agent , cetuximab , reasonable strategy chemotherapy development advance gastric cancer , investigator study rationale .</brief_summary>
	<brief_title>Study XELOX With Cetuximab Advanced Gastric Cancer</brief_title>
	<detailed_description>There presently chemotherapy regimen consider global standard care patient AGC , still need new agent and/or regimen improve efficacy safety chemotherapy advance stomach cancer . The combination 5-fluorouracil plus cisplatin ( FP ) widely use first-line treatment advance gastric cancer many country . Randomized phase III trial investigate capecitabine plus cisplatin ( XP ) versus FP show XP least good FP improve patient ' preference . A Phase II study capecitabine plus oxaliplatin ( XELOX ) conduct study group .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Having give sign write informed consent Patients must histologically cytologically document stomach adenocarcinoma include adenocarcinoma esophagogastric junction . Patients must unresectable metastatic disease recurrent disease curative surgical resection unidimensionally measurable disease accord RECIST ( least long diameter 1 cm compute tomography scan , least 2 cm chest xray physical examination Age 18 70 year old Estimated life expectancy 3 month ECOG performance status &lt; 2 ( See Appendix E ) Adequate bone marrow function ( WBC &gt; 3,000/µL , ANC &gt; 1,500/µL , platelet &gt; 100,000/µL , Hb &gt; 8g/dl ) Adequate kidney function ( creatinine &lt; 1.5 mg/dL ) Adequate liver function [ bilirubin &lt; 2.0 mg/dL , transaminases level &lt; 3 time Upper Normal Value ( 5 time patient liver metastasis ) ] Prothrombin time le 50 % Lower Normal Value No prior chemotherapy No prior radiation therapy Patients must psychological , familial , sociological geographical condition permit medical followup compliance study . Women childbearing potential must negative serum HCG pregnancy test admission . Men woman reproductive potential must agree use effective method contraception treatment 6 month study treatment . Past concurrent history neoplasm gastric adenocarcinoma within last five year , except curatively treat nonmelanoma skin cancer situ carcinoma cervix uterus . Central nervous system ( CNS ) metastases . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study treatment start Gastric outlet obstruction , intestinal obstruction obvious peritoneal seed . Evidence serious gastrointestinal bleeding . The patient bony lesion sole evaluable disease . Pregnant lactate woman , woman childbearing potential employ adequate contraception . Patients sensory neuropathy ( grade &gt; 1 accord NCI CTCAE v. 3.0 ) . Hypersensitivity study drug ingredient . Other serious illness medical condition would allow study participation best interest patient decide investigator . Unstable cardiac disease despite treatment , myocardial infarction within 6 month prior study entry . History significant neurologic psychiatric disorder include dementia seizure . Active uncontrolled infection . Preexisting clinically significant diarrhea . Unstable diabetes mellitus . Severe hypercalcemia &gt; 12 mg/dL uncontrolled bisphosphonates . Active disseminate intravascular coagulation . Concurrent treatment corticosteroid ( equivalent ) except use prophylactic medication regimen , treatment acute hypersensitivity reaction nausea , unless chronic treatment ( initiate &gt; 6 month prior study entry ) low dose ( &lt; 20 mg methyl prednisolone equivalent ) . Concomitant administration experimental drug investigation within 4 week study . Concomitant previous hormonal therapy , immunotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>cetuximab</keyword>
	<keyword>capecitabine</keyword>
	<keyword>oxaliplatin</keyword>
</DOC>